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decisión desde la perspectiva de un tercer pagador y con tasas de eventos anuales. 
La eficacia de la profilaxis se tomó de la literatura. Los costos incluyeron FVIII, 
hospitalización, consultas por urgencias, colocación y complicaciones del catéter 
venoso central y consultas médicas. La tasa de descuento fue 3% y la utilización de 
recursos se identificó del grupo económico de hemofilia Europeo y se valoró a partir 
de tarifarios locales. La prevalencia de hemofilia se determinó con datos locales. 
Dosis de profilaxis con FVIII: 25U/kg tres veces semanales. Dosis del tratamiento a 
demanda: 40U/kg dos veces diarias por 3,5 días. ResultAdos: En adolescentes de 
10 años y 33kg, la profilaxis con FVIII evitará 118 episodios de sangrado y 47 hemor-
ragias articulares durante el resto de sus vidas, versus a demanda; ICER para el san-
grado fue $6.749 y $17.178 para hemorragias articulares. En adolescentes de 19 años 
y 54kg, la profilaxis con FVIII versus a demanda, evitará 87 episodios de sangrado 
y 34 hemorragias articulares durante el resto de sus vidas; ICER para el sangrado 
fue $11.750 y para hemorragias articulares $29.938. ConClusiones: La profilaxis 
con FVIII es una estrategia costo-efectiva en niños con hemofilia A moderada y que 
presenten 6,4 episodios de sangrado y 2,3 hemorragias articulares, en promedio 
cada año. Si la profilaxis se inicia a una edad más temprana, se prevendrán más 
episodios de sangrado y de hemorragia articular.
PND10
ANálisis De Costo-efeCtiviDAD Dl trAtAmieNto ProfiláCtiCo versus A 
DemANDA eN ADultos JóveNes CoN HemofiliA A severA eN ColombiA
Ordoñez Molina J.E., Orozco Giraldo J.J.
CES University, Medellin, Colombia
objeCtivos: La profilaxis con Factor VIII (FVIII) en hemofilia A severa se utiliza 
en países desarrollados, en países en desarrollo hay controversia por sus costos. 
El objetivo de este estudio fue estimar la razón de costo-efectividad incremental 
(ICER) de profilaxis con FVIII versus tratamiento a demanda para prevenir episo-
dios de sangrado y hemorragias articulares en adultos con hemofilia A severa en 
Colombia. MetodologíAs: Se utilizó un árbol de decisión desde la perspectiva del 
tercer pagador y con tasas de eventos anuales. La eficacia de la profilaxis se tomó 
de la literatura. Los costos incluyeron FVIII, hospitalización, consultas por urgen-
cias, colocación y complicaciones del catéter venoso central, consultas médicas y 
días de trabajo perdidos. La tasa de descuento fue 3% y la utilización de recursos 
se identificó del grupo económico de hemofilia Europeo y se valoró a partir de tari-
farios locales. La prevalencia de hemofilia se determinó con datos locales. Dosis de 
profilaxis con FVIII: 25U/kg tres veces semanales. Dosis del tratamiento a demanda: 
50U/kg tres veces diarias por una semana durante la hospitalización y 25U/kg tres 
veces semanales por tres semanas ambulatoriamente. ResultAdos: En adultos 
de 20 años y 70kg, la profilaxis con FVIII evitará 168 episodios de sangrado y 66 
hemorragias articulares durante el resto de su vida, versus a demanda; ICER para el 
sangrado fue $5.676 y $14.463 para hemorragias articulares. En adultos de 40 años 
y 70kg, la profilaxis con FVIII evitará 79 episodios de sangrado y 31 hemorragias 
articulares durante el resto de su vida, versus a demanda; ICER para el sangrado 
fue $5.244 y para hemorragias articulares $13.417. ConClusiones: La profilaxis 
con FVIII en pacientes adultos mejora los resultados clínicos versus a demanda. Si 
la profilaxis se inicia a una edad más temprana, se prevendrán más episodios de 
sangrado y de hemorragia articular.
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Cost-effeCtiveNess ANAlyses of NAtAlizumAb for 2ND liNe versus 
GlAtirAmer ACetAte iN tHe treAtmeNt of relAPsiNG-remittiNG 
multiPle sClerosis PAtieNts iN brAzil
Nishikawa A.M.1, Paladini L.1, Liamas A.L.2, Bueno C.C.1, Clark O.A.C.1
1Evidencias, Campinas, Brazil, 2Biogen Idec Brasil, São Paulo, Brazil
objeCtives: Multiple sclerosis (MS) is a neurologic disease that can dramatically 
affect patients. The aim of this study is to conduct a cost-effectiveness analysis of 
natalizumab (Tysabri®) versus glatiramer acetate (Copaxone®) for treatment of 
Relapsing Remitting Multiple Sclerosis (RRMS) patients from the Brazilian Public 
Healthcare System (SUS) perspective. Methods: A Markov model with a 20-year 
time horizon comparing natalizumab to glatiramer acetate was developed. Health 
states were based on EDSS and relapses (moderate or severe). We obtained relapse 
and disability progression transition probabilities from natural history studies 
on RRMS patients. In each monthly cycle, patients can discontinue treatment, 
remain stable, progress to higher MS EDSS state, experience Progressive Multifocal 
Leukoencephalopathy (PML) or die. Patients with EDSS score ≥ 7.5 receive best sup-
portive care. Resource use and costs were validated by an expert’s panel and valued 
using Brazilian public official lists (DATASUS and BPS). Costs and outcomes (5%) were 
discounted. Probabilistic sensitivity analyses (PSA) covered variability in efficacy 
and costs. Results: Use of natalizumab was associated with slower EDSS pro-
gression and reduced relapse burden. The life years gained (LYG) with natalizumab 
and glatiramer acetate was 10.65 and 10.09, respectively. Costs associated with 
natalizumab were USD 119.330 and USD 102.275 for glatiramer acetate. Incremental 
cost-effectiveness rate for natalizumab versus glatiramer acetate was USD 30.251/
LYG. PSA has confirmed the consistency of base case results. ConClusions: For 
a patient with RRMS, this model shows that natalizumab was cost-effective when 
compared to treatment with glatiramer acetate, assuming the threshold of USD 
50.000/LYG commonly mentioned by the Ministry of Health in Brazil.
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Cost-effeCtiveNess ANAlyses of NAtAlizumAb for 1st liNe versus 
iNterferoN betA-1A 44 mCG iN tHe treAtmeNt of HiGHly ACtive 
relAPsiNG-remittiNG multiPle sClerosis PAtieNts iN brAzil
Nishikawa A.M.1, Paladini L.1, Liamas A.L.2, Bueno C.C.1, Clark O.A.C.1
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objeCtives: Multiple sclerosis (MS) is a neurologic disease that can dramatically 
affect the patient. The aim of this study is to conduct a cost-effectiveness analysis of 
natalizumab (Tysabri®) versus interferon beta-1a (IFNB1a) 44mcg (Rebif®) for treat-
ing Highly Active Relapsing Remitting Multiple Sclerosis (HARRMS) patients. IFNB1a 
yearly frequency and average consumption. Results: The study enrolled 210 MS 
patients, mean age was 40.7 [standard deviation= 11.5] years and 70.7% female. 
Patients with mild disability (according to self-reported Expanded Disability Status 
Scale [EDSS]) represented 40.4% of patients, 43.7% had moderate disability and 15.9% 
had severe disability. The overall yearly direct costs (mean [CI95%]) associated to 
patients with mild, moderate and severe disabilities were: USD18,475 [2,293-34,657], 
USD19,371 [4,651-34,090], and USD19,545 [0-57,659] (1BRL = 0.4937USD), respectively. 
Disease modifying therapies (DMTs) were the major component of the total yearly 
cost, ranging from 93.5% among mild patients to 53.9% in the severe group (85.5% 
in the total sample), followed by aids and home modifications (mild: 2.3%; moder-
ate: 2.3%; severe: 15.1%; total sample: 4.3%). Patients with moderate disability had 
higher absolute costs related to inpatient care, emergency visits, laboratory and 
imaging tests, and DMTs than the other disability groups, while those with severe 
disabilities presented higher costs in the remaining categories (consultations, co-
medications and OTC medications, aids and home modifications, and professional 
caregiver). ConClusions: To our knowledge, this is the first Brazilian study investi-
gating the cost of MS patients. Our findings indicate that MS represent a significant 
economic burden for both the health care system and patients and their families, 
with different expenditures profiles depending on the EDSS level.
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ArGeNtiNiAN survey iN Cost of illNess AND uNmet NeeDs iN multiPle 
sClerosis: treAtmeNt exPerieNCe & tHe Costs of ms PAtieNts iN 
ArGeNtiNA
Kuperman G.
Novartis Argentina, Buenos Aires, Argentina
objeCtives: The objective of the study was to assess the cost of MS patients in 
Argentina categorized by disease severity using a societal perspective. Methods: 
This was a cross-sectional study including MS patients from 21 MS centers in 12 
cities of Argentina conducted to collect information on demographics, disease 
characteristics, disease severity, comorbidities, relapses, resource utilization and 
patient reported outcomes, associated with MS. Patients were stratified by dis-
ease severity using the EDSS (group 1 with EDSS score between 0 and 3; group 2 
with EDSS > 3 and < 7; group 3 with EDSS ≥ 7). Direct and indirect costs included 
in the analysis were: inpatient and outpatient care for relapses, inpatient care for 
other reasons than relapses, consultations, investigations, specific MS treatments, 
wheelchair, professional care, informal care, sick leave and retirement due to MS. 
Second quarter 2012 costs were obtained from public sources and converted to US 
Dollars. Results: A total of266 patients were included. 87.6% had relapsing remit-
ting MS. Mean annual cost per MS patient was USD 36,025 (95% CI 31,985-38,068) for 
patients with an EDSS between 0-3; USD 40,705 (95% CI 37,199-46,300) for patients 
with EDSS > 3 and < 7, and USD 50,712 (95% CI 47,825-62,104) for patients with EDSS 
≥ 7. ConClusions: This is the first Argentine study evaluating the costs of MS 
considering disease severity.
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CHArACteristiCs of HosPitAlizAtioNs Due to AN ePisoDe of 
relAPse iN multiPle sClerosis brAziliAN PAtieNts: A retrosPeCtive 
ADmiNistrAtive ClAims ANAlysis uNDer tHe PubliC PAyer PersPeCtive
Takemoto M.L.S., Guerra R., Fernandes R.A., Takemoto M.M.S., Santos P.M.L., Haas L.C.,  
Silva M.A.
ANOVA, Rio de Janeiro, Brazil
objeCtives: To describe hospital admissions for managing multiple sclerosis (MS) 
relapses in the Brazilian Public Healthcare System (BPHS). Methods: Data from 
the 2009-2012 period were collected from the BPHS Hospital Information System 
(SIH/SUS), which aggregates administrative data from inpatient admissions in public 
hospitals in the entire country. Individual claims coded as “MS Relapse Inpatient 
Treatment” in the SIH/SUS (regardless ICD-10 codes) were identified in the database 
and compiled by state and year. Results: We obtained data on 5,922 individual 
MS relapse-related claims, homegenously distributed among the 4 years. They 
represented an overall cost of BRL3,729,921 for the 2009-2012 period (ranging from 
BRL806,722 in 2010 to BRL1,033,649 in 2012). The 4-year national average cost per 
inpatient admission BRL629, with mean LOS of 7.51 days and ICU days of 0.22. The 
in-hospital mortality rate ranged from 0.65%-1.60%. The 2012 national rate of MS 
relapse-related hospitalization in the general population (per 100,000, absolute num-
ber of admissions / total population) was 0.79, varying from 0.03/100,000 in Alagoas 
(Northeast region) to 1.78/100,000 in Santa Catarina (South region). All parameters 
were consistently different among Brazilian states. In-hospital deaths were very rare 
in this sample not allowing robust conclusions. It was possible to identify significant 
outliers in the mean cost per admission when states were separately considered (2012 
data: from BRL323 [n= 3] in Sergipe to BRL 4,596 in Espírito Santo [n= 4]). São Paulo was 
the state with higher absolute number of hospitalizations in all years. In 2012, the 
state had 526 admissions, mean cost per event of BRL810, 4 in-hospital deaths (0.76%), 
mean LOS= 6.16, and mean ICU days of 0.36. ConClusions: BPHS administrative 
hospital database can provide insightful information about MS relapse-related admis-
sions. Both geographical and time trends can be examined using SIH/SUS secondary 
data, particularly for diseases with highly specific procedure codes.
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ANálisis De Costo-efeCtiviDAD Del trAtAmieNto ProfiláCtiCo versus 
A DemANDA eN ADolesCeNtes CoN HemofiliA A severA eN ColombiA
Ordoñez Molina J.E., Orozco Giraldo J.J.
CES University, Medellin, Colombia
objeCtivos: Algunos adolescentes con hemofilia A moderada reciben profilaxis 
con Factor VIII (FVIII), pero los resultados económicos de esta estrategia de tratami-
ento son desconocidos. El objetivo de este estudio fue estimar la razón de costo-
efectividad incremental (ICER) de profilaxis con FVIII versus tratamiento a demanda 
para prevenir episodios de sangrado y hemorragias articulares en adolescentes 
con hemofilia A moderada en Colombia. MetodologíAs: Se utilizó un árbol de 
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Treatments administered with more convenient devices such as DPIs and shorter 
administration times are associated with higher utility and higher stated adherence 
in adult and pediatric patients.
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Silva N.L.1, Takemoto M.2, Damasceno B.3, Fragoso Y.D.4, Finkelsztejn A.5, Gomes M.1
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objeCtives: Fatigue is one of the most frequent symptoms in patients with 
multiple sclerosis (MS). This study aimed to examine the severity and impact 
of fatigue in MS Brazilian patients. Methods: This was a cross-sectional, mul-
ticenter study conducted in 8 Brazilian major MS treatment sites. Fatigue was 
assessed using the Brazilian version of the Modified Fatigue Impact Scale (MFIS), 
which evaluates the impact of fatigue on 3 dimensions of patients’ daily life: 
physical, cognitive and psychosocial. The patient scores 0 (lower impact) to 84 
points (higher impact). The final score was classified according to the level of 
impact: absent (0-38), low (39-58), and high (> 58). Results: The study enrolled 
210 MS patients, of which the mean age was 40.7 [standard deviation = 11.5] years 
and 70.7% were female. Patients with mild disability (according to self-reported 
Expanded Disability Status Scale [EDSS]) represented 40.4% of patients, 43.7% 
had moderate disability and 15.9% had severe disability. In the overall sample, 
the impact of fatigue was considered absent, low and high in 49%, 32% and 19% 
of patients, respectively. Any impact (both low and high summed) was reported 
by 33%, 63%, and 66% of patients with mild, moderate and severe disability, 
respectively. The mean MFIS total score for mild, moderate and severe patients 
was 29.3, 45.0, and 45.4 (38.6 in the total sample). The mean impact scores for 
each domain in the total sample were 20.0 (physical, range 0-36), 14.7 (cogni-
tive, range 0-40), and 3.9 (psychosocial, range 0-8), meaning that fatigue has a 
proportionally higher impact in the physical than the cognitive or psychosocial 
domains. ConClusions: Our findings indicate that over 50% of MS Brazilian 
patients notice some adverse impact of fatigue in their daily lives, particularly 
related to the physical domain.
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burDeN of multiPle sClerosis AND uNmet NeeDs iN brAzil: 
meAsuremeNt of HeAltH-relAteD QuAlity of life usiNG eQ-5D
Silva N.L.1, Takemoto M.2, Damasceno B.3, Fragoso Y.D.4, Finkelsztejn A.5, Gomes M.1
1Novartis Biociências S.A., São Paulo, Brazil, 2ANOVA - Knowledge Translation, Rio de 
Janeiro, Brazil, 3UNICAMP - Hospital de Clínicas, Campinas, Brazil, 4UNIMES - Universidade 
Metropolitana de Santos, Santos, Brazil, 5Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
objeCtives: To measure the health-related quality of life (HRQL) of multiple 
sclerosis (MS) patients and examine potential associations between HRQL and 
patients’ characteristics. Methods: This was a cross-sectional, multicenter study 
conducted in 8 Brazilian major MS treatment sites. HRQL was assessed using the 
Brazilian version of the EQ-5D and patients self-evaluated their HRQL and health 
status using five dimensions (mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression) and a visual analog scale (VAS). The EQ-5D index 
was calculated based on the value set derived from the UK population, since the 
Brazilian value set is not available. Results: The study enrolled 210 MS patients, 
of which the mean age (standard deviation [SD]) was 40.7 [11.5] years and 70.7% 
were female. Patients with mild disability (according to self-reported Expanded 
Disability Status Scale [EDSS]) represented 40.4% of patients, 43.7% had moderate 
disability and 15.9% had severe disability. Among the 5 assessed HRQL dimensions, 
the ones with higher frequency of self-reported severe limitations were usual 
activities and anxiety/depression (11.0% each). The least impaired dimension was 
self-care, with 63.0% of patients reporting absence of limitation. The mean [SD] VAS 
score was 71.6 [18.9]. The mean EQ-5D index for each level of EDSS (mild, moder-
ate or severe disability) was 0.73 [0.21], 0.49 [0.30], and 0.30 [0.34], respectively. 
In the multivariate analysis, variables related to patients’ characteristics were 
explored and the following were associated with the presence of any limitation 
in at least one dimension: older age, unemployment/retirement, relapses in the 
previous year, emergency department visits in the previous 6 months and lower 
educational level. ConClusions: MS adversely impact patients’ HRQL, especially 
with disability progression and clinical features that can be linked to more severe 
disease.
NeuroloGiCAl DisorDers – Health Care use & Policy studies
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evAluAtioN of treAtmeNt PAtterNs AND CliNiCAl triAls PublisHeD oN 
PAtieNts DiAGNoseD witH iNsomNiA: A literAture uPDAte
Greene N.1, Greene M.2
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Georgia State 
University, Bethel, MA, USA
objeCtives: To conduct a systematic review of literature in peer-reviewed jour-
nals on real world treatment patterns and clinical trials on patients diagnosed 
with Insomnia. Methods: A comprehensive literature search was performed 
using relevant search terms to identify articles published from 2000 to 2010 on 
the real world treatment patterns and clinical trials conducted on patients with 
Insomnia. Studies were identified through electronic Embase, Cochrane, Medline, 
and PubMed databases. Additional parameters were placed on the final search 
strategy to limit the retrieval to articles written in English, involving human sub-
jects. Results: Our search yielded 1,153 articles for treatment patterns and clini-
cal trials on patients diagnosed with Insomnia from PubMed/Medline/Embase/
Cochrane databases. After removing duplicates and non-relevant articles, 65 
articles were included for final review. A total of 16 studies had some focus on 
44mcg was chosen as comparator since it is the most widely prescribed disease 
modifying therapy for 1st-line treatment in HARRMS patients in Brazil. Methods: 
We developed a Markov model with 20-year time horizon comparing natalizumab 
to IFNB1a 44mcg. Health states were based on EDSS and relapses (moderate or 
severe). Since there are no published data evaluating long-term course specifically 
in HARRMS, we assumed transition probabilities on EDSS states based on natural 
history studies on unselected RRMS patients, and relapse probabilities based on 
a post-hoc analysis of the pivotal natalizumab AFFIRM trial. This is a rather con-
servative approach, since disability progression may be slower in this proposed 
model then expected for patients with HARRMS and so the benefit from natali-
zumab could be underappreciated. In each monthly cycle, patients can discontinue 
treatment, remain stable, progress to higher EDSS state, experience Progressive 
Multifocal Leukoencephalopathy or die. Patients with EDSS score≥ 7.5 receive best 
supportive care. Resource use and costs were validated by an expert’s panel and 
valued using Brazilian public official lists (DATASUS and BPS). Costs and outcomes 
were discounted (5%). Probabilistic sensitivity analyses (PSA) covered variability in 
efficacy and costs. Results: Use of natalizumab was associated with slower EDSS 
progression and reduced relapse burden. Life years gained with natalizumab and 
IFNB1a 44mcg were 10.90 and 10.54, and costs were USD119,977 and USD132,446, 
respectively. In the base-case, natalizumab was dominant versus IFNB1a 44mcg. 
PSA has confirmed the consistency of results. ConClusions: For a patient with 
HARRMS, the model shows that natalizumab was dominant when compared to 
IFNB1a 44mcg in the Brazilian Public Healthcare System.
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objeCtives: To assess the health care resource utilization (HRU) of Brazilian mul-
tiple sclerosis (MS) patients. Methods: This was a cross-sectional, multicenter 
study conducted in 8 Brazilian major MS treatment sites. HRU was evaluated as 
the percentage of patients self-reporting the consumption of resources. The main 
categories were: hospitalization, consultations, laboratory and imaging tests, dis-
ease modifying therapies (DMTs), co-medication, aidsand/or home modifications. 
Frequency and average consumption were annualized. Results: The study enrolled 
210 MS patients, mean age was 40.7 [standard deviation= 11.5] years and 70.7% 
female. Patients with mild disability (according to self-reported Expanded Disability 
Status Scale [EDSS]) represented 40.4% of patients, 43.7% had moderate disability 
and 15.9% had severe disability.Hospitalization was reported by 23%, 33% and 15% 
of mild, moderate and severe MS patients, with average length of stay of: 7.53, 10.41, 
and 7.40 days, respectively. Most patients (> 96%) had at least one neurologist con-
sultation per year (average 4.94 visits/year in the total sample). Physical therapy was 
the most consumed non-medical consultation (mild: 11%; moderate: 38%; severe: 
64%). Magnetic resonance imagingwas reported by 60%, 68%, and 55% of mild, mod-
erate and severe patients. Patients using at least one DMT during the previous year 
were: 89%, 93%, and 61% of mild, moderate and severe MS patients, respectively. 
The most prescribed DMT was glatiramer acetate (38%, total sample). The most fre-
quent co-medications were: anti-depressants, anti-spasticity, and analgesics. Home 
modification was reported by 19% and 45% of patients with moderate and severe 
disability, respectively. For ambulation, walking stick was used by 35% of moderate 
patients, while wheelchair was needed by 58% of severe patients. ConClusions: To 
our knowledge, this is the first Brazilian study investigating the HRU of MS patients. 
The findings can be useful to better understand MS patients’ needs in terms of 
comprehensive care.
NeuroloGiCAl DisorDers – Patient-reported outcomes & Patient Preference 
studies
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wHiCH CystiC fibrosis iNHAleD ANtibiotiC meDiCiNe feAtures mAtter 
most to ADult PAtieNts AND PAreNts of PeDiAtriC PAtieNts?
Mohamed A.F.1, Johnson F.R.1, Balp M.M.2, Calado F.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland
objeCtives: To quantify patient and parent preferences and adherence for dif-
ferent administration features of inhaled antibiotic medicines for cystic fibrosis 
(CF). Methods: Adult patients with a self-reported physician diagnosis of CF and 
parents of pediatric CF patients (6 to 17 years) who had Pseudomonas aeruginosa in 
their lung culture at least twice in one year completed a web-enabled, discrete-
choice experiment survey in the United States. Respondents answered 5 treat-
ment-choice questions with known statistical properties. Each question required 
evaluating a pair of hypothetical CF treatment profiles defined by device type (nebu-
lizer, dry powder inhaler (DPI)), total daily administration and cleaning time, dosing 
frequency, dry cough side effect, and personal cost per cycle. Lung function meas-
ured as forced expiratory volume in one second (FEV1) was held constant between 
the hypothetical CF treatment profiles. Stated adherence questions followed two 
randomly selected treatment-choice questions. Random-parameters logit models 
were used to estimate preference weights for all feature levels and the mean rela-
tive importance of each feature for both samples. Results: A total of 209 adult 
patients and 271 parents completed the survey. Mean age of adult patients was 32 
(SD = 10) years and mean age of pediatric patients was 12 (SD = 3) years. Among 
all respondents, the average time spent taking inhaled antibiotic medicines was 
approximately 40 minutes. Relative importance estimates indicated that switching 
from a 30-minute nebulizer twice daily to a 10-minute DPI twice daily was 6.3 times 
more important for adult patients and 2.0 times more important for parents than an 
improvement in dry cough from moderate to mild. Stated adherence for adult and 
pediatric patients was 20-30% higher for DPIs versus nebulizers. ConClusions: 
